Egyptian Biotech Reme-D Secures $500K to Slash Diagnostic Costs
🧬 Meet Reme-D
-
Egypt-based biotech Reme-D makes molecular diagnostic kits for areas where hospital infrastructure is thin.
-
They’ve just landed a $500,000 equity investment from the Global Innovation Fund.
-
Investor check. They previously picked up support from the Oman Technology Fund and the Mohammed Bin Rashid Innovation Fund.
🌡️ The Fridge Problem
-
Standard PCR tests usually need a strict cold chain to stop chemicals from spoiling. But in Sub-Saharan Africa, only half of hospitals have steady electricity, making imported chilled kits expensive and wasteful.
-
Reme-D’s tech fixes this logistics gap so patients in remote areas get treated for infectious diseases on time.
🧪 Stable Science
-
The team uses freeze-drying and nanotechnology to build kits that sit on a shelf at room temperature for months.
-
They currently supply 92 facilities across Egypt, Iraq, Sudan, and Kenya, testing about 50,000 people every month.
-
CEO Salma Tammam has spent 15 years in nanomedicine and previously ran the national COVID-19 testing consortium in Egypt.
📈 Scaling Up
-
The new money will help quadruple their Cairo factory size to 2,000 square meters by the end of 2026.
-
Their local production aims to cut the price of medical testing by 40% compared to buying from the West.